Kolinko L. M., Mishchenko I. V., Kokovskaya O. V.

LITERATURE REVIEWS

Scentific article

Phenylketonuria is one of the most common genetic diseases among the European population that manifests by increased blood phenylalanine content. It has been proven that diet therapy by restricting or excluding phenylalanine is vital for this group of population. Until now, Ukraine has not considered the issue of the quantitative composition of essential amino acids required in the therapeutic amino acid dietary products. Therefore, the aim of this study is to determine the quantitative composition of essential L-amino acids in the therapeutic dietary products for people with phenylketonuria.Mutations in the phenylalanine hydroxylase (PAH) gene and impaired metabolism of the tetrahydrobiopterin cofactor (BH4) lead to phenylalanineemia and the development of phenylketonuria of various forms. Control of phenylalanine (Phe) levels in the blood is only possible by keeping the diet therapy, which includes three key elements: restriction of natural proteins, consumption of products containing L-amino acids without Phe and low-protein food. The composition of the food product for special therapeutic purposes (blended amino acid products) for people with phenylketonuria includes substances containing L-amino acids, micro- and macronutrients, vitamins, sometimes carbohydrates, fats and other nutrients. The quantitative and qualitative composition of a special product should contain a significant proportion of essential amino acids as components of the body nitrogen balance and essential for metabolism. According to the literature about the peculiarities of the breakdown and absorption of essential amino acids, and taking into account desirable blood Phe content, the amount of the amino acids in the blend should be at least 100%, and according to European recommendations, even by 40% higher, when compared with the amino acid composition recommended by WHO / FAO / UNU (2007). This amount of essential amino acids improves the blood Phe content in people with phenylketonuria. Thus, the amount of amino acid composition and the required proportion of essential amino acids in the blended amino acid therapeutic products should be well-balanced and comparable to the age-related nutrition needs for people with various forms of phenylketonuria.

phenylketonuria, phenylalanine, diet therapy, essential amino acids.

1. MOZ Ukrainy. Nakaz MOZ Ukrainy № 760 Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Fenilketonuriia ta inshi hiperfenilalaninemii vid 19.11.2015 [Internet]. Kyyiv: MOZ Ukrainy; 2015. Dostupno: https://cutt.ly/6UHXK5n. [in Ukrainian].
2. Stone WL, Basit H, Los E. Phenylketonuria [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://cutt. ly/7UHX5zy.
3. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev. 2008 Feb;29(1):31-41.
4. Jaffe EK. New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab. 2017 Aug;121(4):289-296. DOI: 10.1016/j.ymgme.2017.06.005.
5. van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021 May 20;7(1):36. DOI: 10.1038/s41572-021-00267-0.
6. Blau N. Genetics of Phenylketonuria: Then and Now. Hum Mutat. 2016 Jun;37(6):508-15. DOI: 10.1002/humu.22980.
7. Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. Anal Biochem. 2000 May 1;280(2):242-9. DOI: 10.1006/abio.2000.4542.
8. Sumaily KM, Mujamammi AH. Phenylketonuria: A new look at an old topic, advances in laboratory diagnosis, and therapeutic strategies. Int J Health Sci (Qassim). 2017 Nov-Dec;11(5):63-70.
9. Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007 Sep-Oct;92(1-2):63-70. DOI:
10. 1016/j. ymgme.2007.05.006.10.The American College of Medical Genetics and Genomics Therapeutic Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16:188-200. DOI: https://doi.org/ 10.1038/gim.2013.157.
11.  van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017 Sep;5(9):743-756. DOI: 10.1016/S2213-8587(16)30320- 5.
12. van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017 Oct 12;12(1):162. DOI: 10.1186/s13023-017-0685-2.
13. Rocha JC, MacDonald A. Dietary intervention in the management of phenylketonuria: current perspectives. Pediatric Health Med Ther. 2016;7:155-163. DOI: doi.org/10.2147/PHMT.S49329.
14. Lee PJ, Amos A, Robertson L, Fitzgerald B, Hoskin R, Lilburn M, et al. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):631-5. DOI: 10.1136/ jnnp. 2008.151175.
15. MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, Bélanger-Quintana A, Burlina A, et al. PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020 Jun 30;15(1):171. DOI: 10.1186/s13023-020-01391-y.
16. MOZ Ukrainy. 2/3 usikh khvorob Ukrainy ye naslidkom nepravylnoho kharchuvannia [Internet]. MOZ Ukrainy: Zdorove kharchuvannia; 2017 Trav 30. Dostupno: https://moz.gov.ua/article/news/23-usih-hvorob-v-ukraini-e-naslidkom-nepravilnogo-harchuvannja. [in Ukrainian].
17. Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur J Pediatr. 1996 Jul;155(1):125- 9. DOI: 10.1007/pl00014228.
18. Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition. World Health Organ Tech Rep Ser. 2007;935:1-265.
19. National Research Council (US) Subcommittee on the Tenth Edition of the Recommended Dietary Allowances. Recommended Dietary Allowances. 10th Edition. Washington (DC): National Academies Press (US); 1989. 302 p. DOI: 10.17226/1349.
20. Kriengsinyos W, Wykes LJ, Ball RO, Pencharz PB. Oral and intravenous tracer protocols of the indicator amino acid oxidation method provide the same estimate of the lysine requirement in healthy men. J Nutr. 2002 Aug;132(8):2251-7. DOI: 10.1093/jn/132.8.2251.
21. Borovik TE, Ladodo KS, Bushueva TV, Timofeeva AG, Kon’ IY, Kruglik VI, et al. Diyetoterapiya pri klassicheskoy fenilketonurii: kriterii vybora spetsializirovannykh produktov bez fenilalanina. Voprosy sovremennoy pediatrii. 2013;12(5):40-48. [in Russian].
22. Zello GA, Pencharz PB, Ball RO. Dietary lysine requirement of young adult males determined by oxidation of L-[1-13C] phenylalanine. Am J Physiol. 1993 Apr;264(4):677-85. DOI: 10.1152/ajpendo.1993.264.4.E677.
23. Bross R, Ball RO, Clarke JT, Pencharz PB. Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation. Am J Physiol Endocrinol Metab. 2000 Feb;278(2): 195-201. DOI: 10.1152/ajpendo.2000.278.2.E195.
24. Leverton RM, Johnson N, Ellison J, Geschwender D, Schmidt F. The quantitative amino acid requirements of young women.IV. Phenylalanine, with and without tyrosine. Journal of Nutrition. 1956;58:341-353
25. Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. Am J Dis Child. 1990 May;144(5):539-43. DOI: 10.1001/archpedi.1990.02150290033020.

«Bulletin of problems biology and medicine» Issue 1 (163), 2022 year, 44-49 pages, index UDK 616.899-002:577.112.3

10.29254/2077-4214-2022-1-163-44-49